An SBOM is now table-stakes for FDA cybersecurity review - and the most common reason packages get rejected at Technical Screening. This hub covers our SBOM service, format guidance (SPDX 2.3 and CycloneDX 1.4+), the rejection patterns we see most often in deficiency letters, and how SBOMs feed into postmarket vulnerability management with VEX. Every artifact we ship is machine-readable, cryptographically hashed for tamper evidence, and structured to drop directly into the eSTAR cybersecurity sections without translation. We cover first-party code, third-party libraries, embedded OS and bootloader components, companion mobile apps, and cloud back-end services as a single linked assembly.
The short answer
An FDA-acceptable SBOM is machine-readable in CycloneDX or SPDX, covers commercial, open-source, and off-the-shelf software, and carries the metadata reviewers check for: supplier, component name, version, unique identifier, dependency relationship, author, timestamp, support level, and end-of-support date. Section 524B(b)(3) makes it a statutory requirement. Pair it with a VEX document that states exploitability for every known CVE, and with a documented process for regenerating the SBOM on every release.
Machine- and human-readable SBOMs with NTIA minimum elements (superseded by CISA's 2026 Minimum Elements for an SBOM, published July 29, 2026), vulnerability mapping, and end-of-support tracking - built for FDA review.
Once cleared, your device still needs eyes on it. We handle SBOM monitoring, coordinated vulnerability disclosure, patching, and FDA-aligned reporting - delivered as one-off projects or as an annual TPLC Partnership covering an entire product line.
Compensating controls, network isolation, and monitoring for fielded devices that can't be easily updated - keeping clinical operations running without touching the cleared design.
Defined entries from our MedTech Cybersecurity Standards Glossary.
The deficiency letters reviewers most often write on submissions in this topic area. Each links to the full response playbook.
Your SBOM is missing required minimum elements, transitive dependencies, or is delivered in an unsupported format.
Response playbookReviewers cannot find the CVE-to-component or CWE-to-weakness mapping that lets them verify your vulnerability posture.
Response playbookYour VM plan lacks defined triage timelines, a coordinated vulnerability disclosure path, or a documented patch-deploy mechanism.
Response playbookYour post-market plan lacks monitoring, patching commitments, customer communications, or end-of-support handling.
Response playbook30-minute strategy session. No cost, no commitment - just answers from people who've shipped 275+ devices supported.